207 related articles for article (PubMed ID: 24919593)
21. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
22. Methylation of the PTPRO gene in human hepatocellular carcinoma and identification of VCP as its substrate.
Hsu SH; Motiwala T; Roy S; Claus R; Mustafa M; Plass C; Freitas MA; Ghoshal K; Jacob ST
J Cell Biochem; 2013 Aug; 114(8):1810-8. PubMed ID: 23533167
[TBL] [Abstract][Full Text] [Related]
23. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
24. Parkin gene mutations are not common, but its epigenetic inactivation is a frequent event and predicts poor survival in advanced breast cancer patients.
Wahabi K; Perwez A; Kamarudheen S; Bhat ZI; Mehta A; Rizvi MMA
BMC Cancer; 2019 Aug; 19(1):820. PubMed ID: 31429726
[TBL] [Abstract][Full Text] [Related]
25. Detection of aberrant hypermethylated spastic paraplegia-20 as a potential biomarker and prognostic factor in gastric cancer.
Zhang H; Song Y; Xia P; Cheng Y; Guo Q; Diao D; Wang W; Wu X; Liu D; Dang C
Med Oncol; 2014 Feb; 31(2):830. PubMed ID: 24381142
[TBL] [Abstract][Full Text] [Related]
26. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes.
Győrffy B; Bottai G; Fleischer T; Munkácsy G; Budczies J; Paladini L; Børresen-Dale AL; Kristensen VN; Santarpia L
Int J Cancer; 2016 Jan; 138(1):87-97. PubMed ID: 26174627
[TBL] [Abstract][Full Text] [Related]
27. Protein tyrosine phosphatase receptor-type O (PTPRO) is co-regulated by E2F1 and miR-17-92.
Xu X; Hong Y; Kong C; Xu L; Tan J; Liang Q; Huang B; Lu J
FEBS Lett; 2008 Aug; 582(19):2850-6. PubMed ID: 18644370
[TBL] [Abstract][Full Text] [Related]
28. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation mediated silencing of microRNA-874 is a promising diagnosis and prognostic marker in breast cancer.
Zhang L; Yan DL; Yang F; Wang DD; Chen X; Wu JZ; Tang JH; Xia WJ
Oncotarget; 2017 Jul; 8(28):45496-45505. PubMed ID: 28525377
[TBL] [Abstract][Full Text] [Related]
30. E74-like Factor 5 Promoter Methylation in Circulating Tumor DNA as a Potential Prognostic Marker in Breast Cancer Patients.
Salimi M; Rastegarpouyani S
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4035-4041. PubMed ID: 38156835
[TBL] [Abstract][Full Text] [Related]
31. Comparison of methylation profiling in cancerous and their corresponding normal tissues from korean patients with breast cancer.
Jung EJ; Kim IS; Lee EY; Kang JE; Lee SM; Kim DC; Kim JY; Park ST
Ann Lab Med; 2013 Nov; 33(6):431-40. PubMed ID: 24205493
[TBL] [Abstract][Full Text] [Related]
32. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients.
Cho YH; Yazici H; Wu HC; Terry MB; Gonzalez K; Qu M; Dalay N; Santella RM
Anticancer Res; 2010 Jul; 30(7):2489-96. PubMed ID: 20682973
[TBL] [Abstract][Full Text] [Related]
33. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.
Karray-Chouayekh S; Trifa F; Khabir A; Boujelbane N; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
J Cancer Res Clin Oncol; 2010 Feb; 136(2):203-10. PubMed ID: 19657672
[TBL] [Abstract][Full Text] [Related]
34. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Wang BL; Chen L; Yang WT; Shen ZZ; Huang W; Shao ZM
Hum Pathol; 2010 Jan; 41(1):48-58. PubMed ID: 19733895
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy.
Jacob ST; Motiwala T
Cancer Gene Ther; 2005 Aug; 12(8):665-72. PubMed ID: 15803146
[TBL] [Abstract][Full Text] [Related]
36. Large-scale analysis of
Croes L; Beyens M; Fransen E; Ibrahim J; Vanden Berghe W; Suls A; Peeters M; Pauwels P; Van Camp G; Op de Beeck K
Clin Epigenetics; 2018; 10():51. PubMed ID: 29682089
[TBL] [Abstract][Full Text] [Related]
37. [Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer].
Noetzel E; Veeck J; Horn F; Hartmann A; Knüchel R; Dahl E
Pathologe; 2008 Nov; 29 Suppl 2():319-27. PubMed ID: 18807039
[TBL] [Abstract][Full Text] [Related]
38. The novel TP53 3'-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection.
Zeng F; Heng J; Guo X; Wang Y; Wu W; Tang L; Chen M; Wang S; Deng H; Wang J
Breast Cancer Res Treat; 2020 Feb; 180(1):237-245. PubMed ID: 31983017
[TBL] [Abstract][Full Text] [Related]
39. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
[TBL] [Abstract][Full Text] [Related]
40. Frequent epigenetic inactivation of RSK4 by promoter methylation in cancerous and non-cancerous tissues of breast cancer.
Li Q; Jiang Y; Wei W; Ji Y; Gao H; Liu J
Med Oncol; 2014 Jan; 31(1):793. PubMed ID: 24338215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
